Quince Therapeutics (QNCX) Non-Current Deferred Tax Liability (2022 - 2025)
Quince Therapeutics (QNCX) posted quarterly Non-Current Deferred Tax Liability of $5.6 million for Q3 2025, up 3.92% year-over-year from $5.4 million in Q3 2024, and little changed quarter-over-quarter from $5.6 million in Q2 2025.
Quince Therapeutics (QNCX) Non-Current Deferred Tax Liability (2022 - 2025) Analysis & Trends
Quince Therapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $5.6 million for Q3 2025.
- In Q3 2025, Non-Current Deferred Tax Liability rose 3.92% year-over-year to $5.6 million; the TTM figure through Sep 2025 stood at $5.6 million (up 3.92% YoY), while the FY2024 annual figure was $5.0 million, down 71.81% from the prior year.
- Non-Current Deferred Tax Liability for Q3 2025 stood at $5.6 million, roughly flat from $5.6 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $17.6 million in Q4 2023, with the low at $248000.0 in Q2 2022.
- The 4-year median for Non-Current Deferred Tax Liability is $5.2 million (2024), against an average of $5.0 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability jumped 7000.0% in 2023, then sank 71.81% in 2024.
- Quince Therapeutics' Non-Current Deferred Tax Liability stood at $248000.0 in 2022, then surged by 7000.0% to $17.6 million in 2023, then tumbled by 71.81% to $5.0 million in 2024, then grew by 12.69% to $5.6 million in 2025.
- Business Quant data shows QNCX's Non-Current Deferred Tax Liability at $5.6 million in Q3 2025, $5.6 million in Q2 2025, and $5.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.59 Mn |
| Sep 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Mar 31, 2025 | 5.17 Mn |
| Mar 31, 2025 | 5.17 Mn |
| Dec 31, 2024 | 4.96 Mn |
| Dec 31, 2024 | 4.96 Mn |
| Sep 30, 2024 | 5.38 Mn |
| Sep 30, 2024 | 5.38 Mn |
| Jun 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 5.17 Mn |
| Mar 31, 2024 | 5.18 Mn |
| Mar 31, 2024 | 5.18 Mn |
| Dec 31, 2023 | 17.61 Mn |
| Dec 31, 2023 | 17.61 Mn |
| Dec 31, 2022 | 248,000.00 |
| Dec 31, 2022 | 248,000.00 |
| Sep 30, 2022 | 248,000.00 |
| Sep 30, 2022 | 248,000.00 |